What is it about?
Virgin coconut oil (VCO) has been suggested as a potential treatment for improving cognitive function in Alzheimer’s disease (AD) due to its ketogenic and antioxidant properties. Here we report the effects of VCO on cognition in people with AD and how the apolipoprotein E (APOE) ε4 genotype influences cognitive outcomes.
Featured Image
Photo by Pete Godfrey on Unsplash
Why is it important?
This study is the first of its kind and the results showed that, while virgin coconut oil (VCO) did not lead to overall improvements in cognition in individuals with mild-to-moderate Alzheimer’s disease (AD) compared to canola oil over the 24-week period, it did demonstrate benefits for apolipoprotein E (APOE) ε4 carriers. Importantly, VCO did not adversely affect lipid profiles or glycated hemoglobin (HbA1C) levels, indicating its safety for consumption.
Perspectives
I believe this article sheds light on potentially beneficial outcomes of Virgin coconut oil (VCO) for apolipoprotein E (APOE) ε4 carriers without adverse effects on lipid profiles or glycated hemoglobin (HbA1C) levels and be an initiative for future research that delve deeper into the mechanisms underlying these responses and explore the therapeutic potential of VCO in Alzheimer’s disease.
Dr. Malika Gayathri Fernando
Macquarie University
Read the Original
This page is a summary of: Effect of Virgin Coconut Oil Supplementation on Cognition of Individuals with Mild-to-Moderate Alzheimer’s Disease in Sri Lanka (VCO-AD Study): A Randomized Placebo-Controlled Trial, Journal of Alzheimer s Disease, November 2023, IOS Press,
DOI: 10.3233/jad-230670.
You can read the full text:
Contributors
The following have contributed to this page
